JP2019112416A5 - - Google Patents

Download PDF

Info

Publication number
JP2019112416A5
JP2019112416A5 JP2019026073A JP2019026073A JP2019112416A5 JP 2019112416 A5 JP2019112416 A5 JP 2019112416A5 JP 2019026073 A JP2019026073 A JP 2019026073A JP 2019026073 A JP2019026073 A JP 2019026073A JP 2019112416 A5 JP2019112416 A5 JP 2019112416A5
Authority
JP
Japan
Prior art keywords
entinostat
administration
exemestane
combination
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019026073A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019112416A (ja
JP6860949B2 (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2019112416A publication Critical patent/JP2019112416A/ja
Publication of JP2019112416A5 publication Critical patent/JP2019112416A5/ja
Application granted granted Critical
Publication of JP6860949B2 publication Critical patent/JP6860949B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019026073A 2013-05-03 2019-02-15 癌の処置方法 Active JP6860949B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361819505P 2013-05-03 2013-05-03
US61/819,505 2013-05-03

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2016512076A Division JP2016522188A (ja) 2013-05-03 2014-05-02 癌の処置方法

Publications (3)

Publication Number Publication Date
JP2019112416A JP2019112416A (ja) 2019-07-11
JP2019112416A5 true JP2019112416A5 (https=) 2019-09-19
JP6860949B2 JP6860949B2 (ja) 2021-04-21

Family

ID=51843995

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016512076A Pending JP2016522188A (ja) 2013-05-03 2014-05-02 癌の処置方法
JP2019026073A Active JP6860949B2 (ja) 2013-05-03 2019-02-15 癌の処置方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2016512076A Pending JP2016522188A (ja) 2013-05-03 2014-05-02 癌の処置方法

Country Status (6)

Country Link
EP (1) EP2991650A4 (https=)
JP (2) JP2016522188A (https=)
KR (1) KR102337598B1 (https=)
CN (1) CN105492007A (https=)
HK (1) HK1223547A1 (https=)
WO (1) WO2014179738A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180353602A1 (en) * 2015-06-29 2018-12-13 Syndax Pharmaceuticals, Inc. Combination of hdac inhibitor and anti-pd-l1 antibody for treatment of cancer
EP3487492A4 (en) * 2016-07-20 2020-03-11 Eisai R&D Management Co., Ltd. USE OF ERIBULIN AND HISTONE DEACETYLASE INHIBITORS FOR THE TREATMENT OF CANCER
WO2018213665A1 (en) 2017-05-19 2018-11-22 Syndax Pharmaceuticals, Inc. Combination therapies
ES2987794T3 (es) 2018-06-06 2024-11-18 Arena Pharm Inc Procedimientos de tratamiento de afecciones relacionadas con el receptor S1P1
RU2680603C1 (ru) * 2018-11-08 2019-02-25 Ильясов Шамиль Сионович Применение 3-о-сульфамата-16,16-диметил-d-гомоэквиленина для лечения онкологических заболеваний

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080234265A1 (en) * 2005-03-11 2008-09-25 The Regents Of The University Of Colorado Histone Deacetylase Inhibitors Sensitize Cancer Cells to Epidermal Growth Factor Inhibitors
EP2046299A1 (en) * 2006-07-11 2009-04-15 Mutual Pharmaceutical Company, Inc. Controlled-release formulations
WO2009067500A1 (en) * 2007-11-19 2009-05-28 Syndax Pharmaceuticals, Inc. Administration of an inhibitor of hdac
KR20100131477A (ko) * 2008-03-07 2010-12-15 화이자 인코포레이티드 음식 없이 지프라시돈을 투여하기 위한 방법, 투여형 및 키트
US20110182888A1 (en) * 2008-04-08 2011-07-28 Peter Ordentlich Administration of an Inhibitor of HDAC, an Inhibitor of HER-2, and a Selective Estrogen Receptor Modulator
CN103906837A (zh) * 2011-09-02 2014-07-02 辛达克斯制药股份有限公司 治疗乳腺癌的方法

Similar Documents

Publication Publication Date Title
JP2019112416A5 (https=)
US9763898B2 (en) Nutritional composition for promoting musculoskeletal health in patients with inflammatory bowel disease (IBD)
JP2019048843A5 (https=)
JP2022121594A5 (https=)
RU2022102537A (ru) Нейроактивные стероиды, их композиции и применения
JP2014528901A5 (https=)
JP2020519295A5 (https=)
JP2023153863A (ja) 15-hepeを含む組成物及びその使用方法
JP2015503593A5 (https=)
JP2014525465A5 (https=)
JP2013529665A5 (https=)
JP2020532531A5 (https=)
JP2016522188A5 (https=)
JP2017536380A (ja) 15−hepeを含む組成物、およびそれを用いて線維症を処置または防止する方法
JP2020500864A5 (https=)
JPWO2020210418A5 (https=)
JP2016539149A5 (https=)
CN112823795A (zh) 一种特发性肺纤维化药物组合及其应用
Jagmeet et al. Kanchnar Guggulu and Varunadi Kashaya in Hypothyroidism-A Case Study
RU2016136666A (ru) Составы на основе прогестерона
Teng et al. Neuroprotection of maslinic acid, a novel glycogen phosphorylase inhibitor, in type 2 diabetic rats
CN105050607A (zh) 用于治疗关节炎和骨关节炎的方法和组合物
JP2015231976A (ja) 心筋炎の予防または治療剤
Elgamal et al. Some risk factors of gallstone formation after laparoscopic sleeve gastrectomy and the role of ezetimibe versus ursodeoxycholic acid in its prevention
RU2773190C2 (ru) Введение тазимелтеона в условиях натощак